Regeneron seeks US discovery for Taiwanese aflibercept biosimilar patent dispute

Article: Regeneron seeks US discovery for Taiwanese aflibercept biosimilar patent dispute - IAM Skip to main content Home News & Analysis Regeneron seeks US discovery for Taiwanese aflibercept biosimilar patent dispute 5 min read | 13 March 2026 | Adam Houldsworth Adam Houldsworth Shutterstock/Lev Radin Section 1782 is a valuable tool for parties embroiled in patent disputes in jurisdictions where less discovery is available than in the US To read more Register for limited access Register to receive our newsletter and gain limited access to subscriber content.

Register now Subscribe to unlock unlimited access Get news, unique commentary, expert analysis and essential resources from the IAM experts. Subscribe now Already have access? Login below Adam Houldsworth Deputy Editor IAM [email protected] View full biography Related Topics Biotechnology Biotechnology & medical research Healthcare Life Sciences Litigation Patents Pharmaceuticals Pharmaceuticals Pharmaceuticals & chemicals Regeneron Pharmaceuticals Strategy Taiwan US District Court for District of Delaware United States of America Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10 Related The jurisdictional tug-of-war in SEP disputes is rewriting strategy playbooks Yesterday English High Court rules $392 million lump sum payment by Samsung is FRAND for ZTE cross-licence 2 days ago The UPC’s Fujifilm v Kodak decision significantly qualifies its long-arm jurisdiction over the UK 2 days ago Most read 1 New IAM Special Report unpacks IP considerations at the heart of the energy revolution 6 days ago 2 EC rows back LNG “soft safe harbour”; Ericsson proposes ETSI IPR Guide changes; EPO AI invention data; US IP theft hearing; SEP Summit Asia; plus much more 7 days ago 3 China foreign overreach regulations; VLSI v Intel; Anthropic leak lessons; LNG long read; SEP Summit Asia; plus much more 19 April 2026 4 USPTO director to consider US manufacturing and small-business status when instituting or denying inter partes and post-grant review petitions 08 April 2026 5 USPTO revises guidance on design patents for computer-generated interfaces and icons 15 April 2026 6 Human authorship remains cornerstone requirement for copyright registration as Supreme Court denies certiorari in Thaler case 4 days ago 7 USPTO introduces pre-order papers for patent owners in ex parte re-examinations 22 April 2026 8 Chinese courts underscore importance of compliance with moral rights in brand collaborations following high-profile copyright dispute 4 days ago 9 Streaming giants call out Access Advance, ask UK Supreme Court to find patent pools have FRAND obligations 6 days ago 10 Five reasons why courts should not set rates for patent pools 25 April 2026 Table (full screen) − + Unlock unlimited access to all IAM content Subscribe Now